These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23947692

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants.
    Azizi G, Haidari MR, Khorramizadeh M, Naddafi F, Sadria R, Javanbakht MH, Sedaghat R, Tofighi Zavareh F, Mirshafiey A.
    Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):198-206. PubMed ID: 24659124
    [Abstract] [Full Text] [Related]

  • 4. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
    Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, Umeda N, Tanaka Y, Hayashi T, Goto D, Ito S, Sekiguchi K, Sumida T.
    Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
    [Abstract] [Full Text] [Related]

  • 5. The kinase inhibitor imatinib--an immunosuppressive drug?
    Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM.
    Curr Cancer Drug Targets; 2007 May; 7(3):251-8. PubMed ID: 17504122
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R.
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [Abstract] [Full Text] [Related]

  • 8. Imatinib for the treatment of rheumatic diseases.
    Paniagua RT, Robinson WH.
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):190-1. PubMed ID: 17396105
    [No Abstract] [Full Text] [Related]

  • 9. Imatinib: novel treatment of immune-mediated kidney injury.
    Wallace E, Gewin L.
    J Am Soc Nephrol; 2013 Apr; 24(5):694-701. PubMed ID: 23431076
    [Abstract] [Full Text] [Related]

  • 10. Bone metabolism during long-term treatment with imatinib.
    O'Sullivan S, Horne A, Wattie D, Porteous F, Gamble G, Browett P, Grey A.
    Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF, Perry CM.
    Drugs; 2003 Aug; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [Abstract] [Full Text] [Related]

  • 12. Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model.
    Suzuki N, Sasaki N, Utsumi Y, Nagashima H, Nakamura Y, Yamashita M, Yamauchi K, Sawai T.
    Int J Rheum Dis; 2013 Aug; 16(4):455-62. PubMed ID: 23992268
    [Abstract] [Full Text] [Related]

  • 13. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W, Kondo M, Tokoro A.
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [Abstract] [Full Text] [Related]

  • 14. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M.
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Aug; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 17. Imatinib mesylate.
    Waller CF.
    Recent Results Cancer Res; 2010 Aug; 184():3-20. PubMed ID: 20072827
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ.
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [Abstract] [Full Text] [Related]

  • 20. [Treatment with imatinib for refractory PAH].
    Nakamura K, Akagi S, Sarashina T, Ogawa A, Matsubara H, Ito H.
    Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.